Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14078197 | 0.84 | — | — | |
| SCHEMBL12193550 | 0.81 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL12023144 | 0.78 | SMN1; SMN2 (0.42) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL25405239 | 0.77 | ALDH1A1 (0.46) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL9912673 | 0.77 | BCHE (0.38) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL25401470 | 0.77 | ALDH1A1 (0.46) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL3322339 | 0.76 | HPGD (0.40) | BCHESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL971781 | 0.76 | HPGD (0.40) | BCHESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2847700 | 0.76 | HPGD (0.40) | BCHESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3964578 | 0.75 | BCHE (0.36) | BCHEKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |